YWHAG

14-3-3 protein gamma · P61981 · YWHAG on Sugi Atlas →

2,256 patent compounds predicted against YWHAG, 1,632 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7091297 SCHEMBL7091297 0.83 1/20
SCHEMBL7093516 SCHEMBL7093516 0.83 1/20
SCHEMBL7094321 SCHEMBL7094321 0.79 1/20
SCHEMBL7093732 SCHEMBL7093732 0.78 1/20
SCHEMBL7096142 SCHEMBL7096142 0.78 1/20
SCHEMBL2336439 SCHEMBL2336439 0.76 1/20
SCHEMBL7568170 SCHEMBL7568170 0.76 1/20
SCHEMBL7093360 SCHEMBL7093360 0.75 1/20
SCHEMBL79339 SCHEMBL79339 0.74 1/20
SCHEMBL7090990 SCHEMBL7090990 0.74 1/20
SCHEMBL7094651 SCHEMBL7094651 0.74 1/20
SCHEMBL6254176 SCHEMBL6254176 0.73 1/20
SCHEMBL7093716 SCHEMBL7093716 0.71 1/20
SCHEMBL7093542 SCHEMBL7093542 0.71 1/20
SCHEMBL7093650 SCHEMBL7093650 0.71 1/20
SCHEMBL7095149 SCHEMBL7095149 0.69 1/20
SCHEMBL7091071 SCHEMBL7091071 0.68 1/20
SCHEMBL7093127 SCHEMBL7093127 0.68 1/20
SCHEMBL7091074 SCHEMBL7091074 0.68 1/20
SCHEMBL7092943 SCHEMBL7092943 0.68 1/20

Clinical trials — most relevant to YWHAG by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer EARLY_PHASE1COMPLETED
Relationship of YWHAH Polymorphisms to Rheumatoid Arthritis Disease Severity nanCOMPLETED
IVM for Patients With Low Ovarian Response. Does it Improve IVFoutcomes and Does it Improve the Following IVF Cycle? nanUNKNOWN
Semen Analysis Changes in Covid-19 Positivepatients nanCOMPLETED
Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma nanCOMPLETED
Multi-Dimensional Genomic Dissection of Ring Chromosome 14 Syndrome nanACTIVE_NOT_RECRUITING
Blood-based Biomarkers for the Prognosis of Sports Related Concussion nanCOMPLETED
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Cell Membrane Potential Regulates Spatial-Specific Mechanoptosis Resistance and Metastasis in Colorectal Cancer Via Mechanotransduction and the PVR/CD96 Axis nanCOMPLETED
New Signaling Pathway Targeting Systemic Lupus Erythematosus nanUNKNOWN
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma nanUNKNOWN
Developing Genetic Education for Smoking Cessation nanCOMPLETED
The Clinical Study of Sex Chromosome Variants nanCOMPLETED
Biomarkers in Idiopathic Juvenile Arthritis nanUNKNOWN
Immunohistochemical Expression of EGFR in the Patients Having Oral Squamous Cell Carcinoma nanCOMPLETED
Establishing Radiolabelled PSMA as a Target for Glioma Treatment nanNOT_YET_RECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Identification of an Asthma Susceptibility Gene on 3P nanCOMPLETED
Molecular Biomarkers Associated With Degenerative Joint Disease in the Knee nanCOMPLETED
Epithelioid Haemangioendothelioma Observational Study nanRECRUITING
Chromosome 5Q Gene Variants and Asthma-Related Traits nanCOMPLETED
Genetic Studies Spermatogenic Failure nanCOMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Molecular Associations With Reproductive Failure nanCOMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a YWHAG binder may also engage these)

ProteinNameSimilarity
Q5RC20 1.000 Q5RC20 →
Q6PCG0 1.000 Q6PCG0 →
P61982 1.000 P61982 →
P61983 1.000 P61983 →
P68252 1.000 P68252 →
Q6UFZ3 1.000 Q6UFZ3 →
Q6NRY9 1.000 Q6NRY9 →
Q6PC29 1.000 Q6PC29 →
Q5F3W6 1.000 Q5F3W6 →
Q5ZLQ6 1.000 Q5ZLQ6 →
P48347 1.000 P48347 →
YWHAQ 14-3-3 protein theta 1.000 landscape →
Q91896 1.000 Q91896 →
Q52M98 1.000 Q52M98 →
P68250 1.000 P68250 →
P68255 1.000 P68255 →
YWHAZ 14-3-3 protein zeta/delta 1.000 landscape →
Q1HR36 1.000 Q1HR36 →
Q5R651 1.000 Q5R651 →
Q6UFZ9 1.000 Q6UFZ9 →
A4K2U9 1.000 A4K2U9 →
Q6UFZ8 1.000 Q6UFZ8 →
YWHAB 14-3-3 protein beta/alpha 1.000 landscape →
Q4R572 1.000 Q4R572 →
Q7T356 1.000 Q7T356 →
P42649 1.000 P42649 →
P35213 1.000 P35213 →
Q9C5W6 1.000 Q9C5W6 →
C0H4V6 1.000 C0H4V6 →
P29307 1.000 P29307 →